Warfarin

"Warfarin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

An anticoagulant that acts by inhibiting the synthesis of vitamin K-dependent coagulation factors. Warfarin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, pulmonary embolism, and atrial fibrillation with embolization. It is also used as an adjunct in the prophylaxis of systemic embolism after myocardial infarction. Warfarin is also used as a rodenticide.

Descriptor ID	D014859
MeSH Number(s)	D03.383.663.283.446.520.914 D03.633.100.150.446.520.914
Concept/Terms	Warfarin Warfarin 4-Hydroxy-3-(3-oxo-1-phenylbutyl)-2H-1-benzopyran-2-one Apo-Warfarin Apo-Warfarin Aldocumar Aldocumar Gen-Warfarin Gen-Warfarin Warfant Warfant Coumadin Coumadin Marevan Warfarin Potassium Warfarin Potassium Potassium, Warfarin Warfarin Sodium Warfarin Sodium Sodium, Warfarin Coumadine Coumadine Tedicumar Tedicumar

Below are MeSH descriptors whose meaning is more general than "Warfarin".

Chemicals and Drugs [D]
Heterocyclic Compounds [D03]
Heterocyclic Compounds, 1-Ring [D03.383]
Pyrans [D03.383.663]
Benzopyrans [D03.383.663.283]
Coumarins [D03.383.663.283.446]
4-Hydroxycoumarins [D03.383.663.283.446.520]
Warfarin [D03.383.663.283.446.520.914]
Heterocyclic Compounds, Fused-Ring [D03.633]
Heterocyclic Compounds, 2-Ring [D03.633.100]
Benzopyrans [D03.633.100.150]
Coumarins [D03.633.100.150.446]
4-Hydroxycoumarins [D03.633.100.150.446.520]
Warfarin [D03.633.100.150.446.520.914]

Below are MeSH descriptors whose meaning is related to "Warfarin".

Below are MeSH descriptors whose meaning is more specific than "Warfarin".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Warfarin" by people in this website by year, and whether "Warfarin" was a major or minor topic of these publications.

Bar chart showing 83 publications over 27 distinct years, with a maximum of 12 publications in 2011

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1997	1	0	1
1999	1	0	1
2001	0	2	2
2002	0	1	1
2003	0	1	1
2004	0	1	1
2005	1	1	2
2006	2	0	2
2007	1	1	2
2008	1	3	4
2009	1	1	2
2010	1	1	2
2011	10	2	12
2012	4	0	4
2013	5	0	5
2014	4	1	5
2015	3	0	3
2016	1	0	1
2017	1	2	3
2018	3	1	4
2019	3	1	4
2020	3	4	7
2021	1	1	2
2022	1	3	4
2023	1	2	3
2024	0	1	1
2025	2	2	4

Below are the most recent publications written about "Warfarin" by people in Profiles.

Abu HO, Del Castillo FF, Wang W, Saczynski JS, Mehawej J, Tenes P, Tisminetzky M, Gurwitz J, Goldberg RJ, Dosa D, Kapoor A, McManus DD. The prevalence and burden of chronic kidney disease, patterns of anticoagulation prescribing, and major bleeding risk in older adults with atrial fibrillation. BMC Geriatr. 2025 Dec 28; 26(1):138.

View in: PubMed
Ito K. In older, frail, VKA-experienced patients with AF, SD-DOACs vs. warfarin reduced thrombotic events without increasing major bleeding. Ann Intern Med. 2025 Nov; 178(11):JC128.

View in: PubMed
Kan V, Lapane K, McManus D, Baek J, Darling C, Alcusky M. Racial disparities and trends in anticoagulant use among ambulatory care patients with atrial fibrillation and atrial flutter in the United States from 2007 to 2019. BMC Health Serv Res. 2025 Oct 03; 25(1):1300.

View in: PubMed
Lawal OD, Aronow HD, Shobayo F, Zhang Y, Hume AL, Taveira TH, Matson KL, Gold J, Wen X. Restarting Oral Anticoagulation in Patients With Atrial Fibrillation After Admission for a Gastrointestinal Bleeding Event: Effectiveness and Safety of Direct Oral Anticoagulants Compared to Warfarin. Pharmacotherapy. 2025 10; 45(10):638-653.

View in: PubMed
Shu L, Jack N, de Havenon A, Goldstein ED, Khan F, Nguyen TN, Henninger N, Siegler JE, Stretz C, Perelstein E, Kala N, Rana M, Furie KL, Douketis JD, Yaghi S. Risk factors for MACE and bleeding in atrial fibrillation patients undergoing surgery: Insights from the bridge trial. J Stroke Cerebrovasc Dis. 2024 Sep; 33(9):107839.

View in: PubMed
Faisaluddin M, Alwifati N, Naeem N, Balasubramanian S, Narasimhan B, Iqbal U, Dani SS. Safety and Efficacy of Direct Oral Anticoagulants Versus Warfarin for Atrial Fibrillation in End-Stage Renal Disease on Hemodialysis: A Meta-Analysis of Randomized Control Trials. Am J Cardiol. 2023 Nov 01; 206:309-311.

View in: PubMed
Schwann TA, Vekstein AM, Engelman DT, Thibault D, Chikwe J, Engoren M, Gaudino M, Vemulapalli S, Thourani VH, Ailawadi G, Rousou A, Habib RH. Long-term Outcomes and Anticoagulation in?Mitral Valve Surgery-A Report From The?Society of Thoracic Surgeons Database. Ann Thorac Surg. 2023 11; 116(5):944-953.

View in: PubMed
Lawal OD, Aronow HD, Shobayo F, Hume AL, Taveira TH, Matson KL, Zhang Y, Wen X. Comparative Effectiveness and Safety of Direct Oral Anticoagulants and Warfarin in Patients With Atrial Fibrillation and Chronic Liver Disease: A Nationwide Cohort Study. Circulation. 2023 03 07; 147(10):782-794.

View in: PubMed
Ko D, Lin KJ, Bessette LG, Lee SB, Walkey AJ, Cheng S, Kim E, Glynn RJ, Kim DH. Trends in Use of Oral Anticoagulants in Older Adults With Newly Diagnosed Atrial Fibrillation, 2010-2020. JAMA Netw Open. 2022 11 01; 5(11):e2242964.

View in: PubMed
Gupta M, Minhas AMK, Goel SS, Dani SS, Alam M, Nazir S, Khan SU, Aronow W, Jain V. Contemporary trends in utilization and outcomes of percutaneous left atrial appendage occlusion in the United States from 2016 to 2019. Heart Rhythm. 2023 02; 20(2):313-314.

View in: PubMed

People

Explore

Similar Concepts

Top Journals